Trust demands royalties from UCB for Cimzia
The pharmaceutical company is being accused of infringing a patent held by a British charitable trust for its rheumatoid arthritis drug Cimzia. This drug was forecasted to cross $ 2 billion mark for its annual sales as it is widely used to treat inflammation in rheumatoid arthritis and Crohn’s disease.
Cimzia is the brand name for Certolizumab. It reduces inflammation in the body. It is used for treatment of the symptoms of Crohn’s disease. It is also used for treatment of moderate-to-severe rheumatoid arthritis in adults. It is also used for other purposes. It was approved by FDA in April 2008.
Cimzia is a TNF blocker. It is used to treat inflammation in Crohn’s disease. In Crohn’s disease the digestive tract becomes inflamed and adversely affects the gastrointestinal tract. It is also used to reduce or prevent inflammation in rheumatoid arthritis. It blocks TNF and reduces or prevents destruction of joints.
This drug has also been linked with increased risk of developing cancer and other life threatening infections. The side effects of Cimzia include headache, fever, nausea, chills, myalgia, diarrhea, abdominal pain, upper respiratory infection and reactions to the injection area. It has been also associated with severe side effects such as allergic reactions such as hives, difficulty breathing; swelling of your face, lips, tongue, or throat, sweating, chills and tired feeling, feeling short of breath, swelling of ankles or feet, chest pain, swollen glands in neck, armpits, or groin, seizure or convulsions, congestive heart failure, diseases of the nervous system, reduced levels of platelets and red blood cells in the blood, etc. It is being investigated for the potential risk of cancer as well as the risk of developing life-threatening infections.
The case is filed by the Mathilda and Terence Kennedy Institute of Rheumatology Trust. His lawsuit was filed in U.S. federal court in Delaware, demanding royalties and damages. The complaint against UCB alleges that the patent was issued in 2001 and it blames UCB of infringement by the way of promoting the use of Cimzia with methotrexate. Cimzia is one of the hot selling drugs manufactured by UCB. UCB faced trouble as this infringement case came on the verge of patents expiry on some of its big-selling drugs. UCB was riding on high hopes for Cimzia as many of its big selling drugs were due for patent expiry. This case related to Cimzia has caused UCB trouble as it was expecting a high sale of around $2 billion, in the coming years.
The trust has previously sued Amgen Inc (AMGN.O) and Wyeth, a unit of Pfizer Inc (PFE.N), for infringing with their Enbrel arthritis drug a year earlier. That lawsuit was settled with agreement of two companies paying royalties to the trust.
The trust’s lawsuit against UCB cites previous cases where Centocor, Abbott Laboratories, Amgen and Wyeth (Pfizer) had paid to Kennedy tens of millions of dollars in royalties. The case was filed in the Mathilda and could be found as Terence Kennedy Institute of Rheumatology Trust v UCB Inc in the U.S. District Court, District of Delaware.